Monte Rosa Therapeutics (GLUE) Cash from Investing Activities (2020 - 2026)

Monte Rosa Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$261.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 160.4% year-over-year to -$261.0 million; the TTM figure through Mar 2026 stood at -$262.6 million (down 69.93% YoY), while the FY2025 annual figure was -$101.8 million, down 129.09% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$261.0 million, down from -$65.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $38.1 million in Q3 2025, with the low at -$261.0 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $9.9 million (2024), against an average of -$31.6 million.
• Peak annual rise in Cash from Investing Activities reached 1846.98% in 2022, while the deepest fall reached 8042.53% in 2022.
• Monte Rosa Therapeutics' Cash from Investing Activities stood at -$53.9 million in 2022, then jumped by 126.51% to $14.3 million in 2023, then slumped by 316.1% to -$30.9 million in 2024, then plunged by 110.6% to -$65.1 million in 2025, then slumped by 301.13% to -$261.0 million in 2026.
• Business Quant data shows GLUE's Cash from Investing Activities at -$261.0 million in Q1 2026, -$65.1 million in Q4 2025, and $38.1 million in Q3 2025.